DPP-4抑制剂联合格列美脲治疗2型糖尿病的临床研究

Clinical study of the combination of DPP-4 inhibitors and grammethazine in the treatmnet of type 2 diabetes

目的探讨DPP-4抑制剂联合格列美脲治疗2型糖尿病的临床疗效。方法选取2019年6月至2020年7月本院收治的2型糖尿病患者122例,按入院先后顺序分为研究组和对照组,各61例。对照组予以格列美脲治疗,研究组在对照组基础上予以DPP-4抑制剂治疗。比较两组治疗前后糖代谢[空腹静脉血糖(FBG)、餐后2 h血糖(2 h BG)及糖化血红蛋白(HbA_(1)c)]、脂代谢[甘油三酯(TG)、总胆固醇(TC)及低密度脂蛋白胆固醇(LDL-C)]的改善情况、临床疗效及不良反应发生情况。结果治疗2个月后,研究组TG、TC及LDL-C水平均明显低于治疗前,且研究组低于对照组(P<0.05);治疗2个月后,两组FBG、2 h BG及HbA_(1)c水平均明显低于治疗前,且研究组低于对照组(P<0.05);研究组治疗总有效率高于对照组(P<0.05);治疗期间两组均未出现严重不良反应。结论DPP-4抑制剂联合格列美脲治疗2型糖尿病疗效显著且安全可靠,不仅能有效调节血糖、血脂水平,还避免降糖药物导致低血糖反应的发生,有助于患者康复。

Objective To explore the clinical efficacy of DPP-4 inhibitors combined with grammethazine in the treatmnet of 2 diabetes.Methods 122 cases of type 2 diabetes were selected from June 2019 to July 2020 in our hospital,they were divided into study group and control group according to the order of admission,with 61 cases in each group.The control group was treated grammethydine,and the study group was treated with DPP-4 inhibitors on the basis of the control group.The improvement of sugar metabolism[fasting blood glucose(FBG),2 h blood sugar(2 h BG)and glycoglobin(HbA_(1)c)],lipid metabolism(TG),total cholesterol(TC)and low density lipoprotein cholesterol(LDL-C),clinical efficacy and adverse reactions were compared between the two group.Results After 2 months of treatment,the TG,TC and LDL-C levels of the study group were significantly lower than before treatment,and the study group was lower than that of the control group(P<0.05);after 2 months of treatment,the FBG,2 h BG and HbAlc of the study group were significantly lower than before treatment,and the study group were lower than the control group(P<0.05).Conclusion The DPP-4 inhibitor combined with grammethyl in the treatment of type 2 diabetes has significant efficacy and is safe and reliable,which can not only effectively regulate blood sugar and lipid levels,but also avoid the occurrence of hypoglycemia reaction caused by sugarlowering drugs,which can help patients’recover.